BIOCRATES and ALTANA Expand Metabolomics Collaboration
News Apr 06, 2006
Based on successful pilot studies in high-resolution pharmacodynamics, BIOCRATES Life Sciences GmbH and ALTANA Pharma AG signed a collaboration contract comprising joint method development for targeted metabolite profiling as well as further preclinical and clinical studies.
“We are very pleased to gain an innovative pharma partner like ALTANA Pharma in one of our main business areas”, said Armin Graber Ph.D., BIOCRATES’ CEO. “This collaboration will broaden our analytical panel and adapt it to the needs of the pharmaceutical industry.”
The medical focus of the joint projects will be on a better understanding of inflammatory processes in respiratory diseases in view of the development of novel multiparametric biomarkers for drug development and therapy monitoring.
“A targeted and quantitative approach to metabolomics allows to immediately deduce biologically relevant information from the analytical data”, says Klaus Weinberger Ph.D., CSO of BIOCRATES. “Important enzymatic reactions and entire metabolic pathways can now be monitored on a fully standardized basis.”
“Pilot studies in disease model characterization and pharmacodynamics have impressively demonstrated the huge potential of this technology for drug development”, adds Sascha Dammeier Ph.D., Head of Protein Technologies at ALTANA Pharma AG. “We aim at exploiting this potential to obtain additional relevant mode-of-action data in many steps of preclinical and clinical drug development.”
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019